HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Pays $29.3 Mil. To 20 States; Buys Chance To Write PBM Rules

Executive Summary

Medco's $29.3 mil. settlement with 20 state attorneys general looks like a shrewd investment ahead of the Medicare prescription drug law scheduled to take effect in 2006

You may also be interested in...



Medicare Part D Could Alleviate “Bias” In Formulary Decisions

The use of pharmacy & therapeutics committees under the Medicare Part D drug benefit will help alleviate the bias sometimes seen in managed care decision making, Formulary Resources consultant Peter Penna suggested during the National Association of Chain Drug Stores' Medicare Prescription Drugs and Reform Conference in Baltimore March 3

Medicare Part D Could Alleviate “Bias” In Formulary Decisions

The use of pharmacy & therapeutics committees under the Medicare Part D drug benefit will help alleviate the bias sometimes seen in managed care decision making, Formulary Resources consultant Peter Penna suggested during the National Association of Chain Drug Stores' Medicare Prescription Drugs and Reform Conference in Baltimore March 3

PBMs Still In Prosecutors’ Sights; Express Scripts Faces Spitzer

New York Attorney General Eliot Spitzer's suit against Express Scripts represents another high-profile challenge to the pharmacy benefit management business model at a time when the industry hopes to play a prominent role in the Medicare drug benefit

Related Content

UsernamePublicRestriction

Register

PS043872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel